Alprostapint® 500

500 µg (alprostadil)

The synthetic prostaglandin E1 alprostadil is indicated for temporary maintenance of the patency of the ductus arteriosus of newborn infants with congenital cyanotic heart defects, for whom a patency of the ductus is vital.

The medication may be used to maintain the patency of the Ductus Arteriosus Botalli, thereby improving circulation and oxygenation until corrective or palliative surgery can be performed.



Congenital heart defects:

  • Malformations with restricted pulmonary blood flow like pulmonary atresia, pulmonary stenosis, tricuspid artresia, tetralogy of Fallot.
  • Malformations with restricted systemic blood flow like coarctation of the aorta, interruption of the aortic arch with valve stenosis or artresia of the left heart.
  • Transposition of the great vessels with or without other defects.


Severe chronic heart failure in candidate for heart transplant
For these patients with severe illness, the most important
pharmacological effect of alprostadil is the demonstrated hemodynamic improvement by:

  • Increase of the systolic unloading and cardiac output index
  • Decreased systemic blood pressure, pulmonary pressure, right atrial pressure and pulmonary capillary vascular resistance.


Commercial presentation


Alprostapint™ 500 µg is marketed in a box with 1 or 5 ampoules each containing 500µg of alprostadil in a 1 ml ethanolic solution.